Ft. Lauderdale Conference • May 19-20, 2017

The objective of the conference series is to deliver a comprehensive educational update highlighting the most clinically relevant advances in chronic liver and gastrointestinal (GI) diseases. The 1.5-day conferences cover topics ranging from upper GI disorders, viral hepatitis, cirrhosis, inflammatory bowel disease and irritable bowel syndrome.

Welcome/Introduction• Conference Chairs: Maria Abreu, MD and Eugene Schiff, MD

Diagnosis and management of primary biliary cholangitis (PBC)• Cynthia Levy, MD

Advances in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)• Naim Alkhouri, MD

Management of drug-induced liver injury (DILI)• Paul Martin, MD

Advances in opioid-induced constipation management• Baha Moshiree, MD, MS

Fecal incontinence: Sealing the leak• Satish Rao, MD, PhD

Diarrhea: Managing exocrine pancreatic insufficiency (EPI), irritable bowel syndrome (IBS)
and small bowel bacterial overgrowth (SIBO)• Lawrence Schiller, MD

Emerging hepatitis C (HCV) therapies-2017/2018• Robert Brown, MD, MPH

Does curing HCV lead to HBV reactivation and higher risk of hepatocellular carcinoma (HCC)?• Fred Poordad, MD

Complications of cirrhosis: hepatic encephalopathy, ascites and variceal bleeding• Kimberly Brown, MD

HCC: Update on role of metabolic syndrome, screening and treatment• Hashem El-Serag, MD, MPH

Reflux Hypersensitivity: A newly diagnosed esophageal disorder• Ronnie Fass, MD

Impact of weight loss surgery on esophageal function• Michael Vaezi, MD, PhD, MSc

Barrett's esophagus and esophageal cancer-Why can't we have more of an impact?• Joel Richter, MD

Positioning new therapies for ulcerative colitis and Crohn's disease• Stephen Hanauer, MD

The evolving role of therapeutic drug monitoring in inflammatory bowel disease (IBD)• Maria Abreu, MD

Management of celiac disease• Joseph Murray, MD